Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 2178 • ACR Convergence 2023
Increased Risk of Dementia in Patients with Primary Sjogren’s Syndrome: A Nationwide Population-based Cohort Study
Kyung-Ann Lee¹, Hyeji Jeon¹, Hyun-Sook Kim¹ and Gi Hyeon Seo², ¹Soonchunhyang University Seoul Hospital, Seoul, South Korea, ²Health Insurance Review and Assessment Service, Wonju, South Korea
Background/Purpose: Autoimmunity and systemic inflammation may play a role in early-stage dementia. Few studies have investigated whether primary Sjogren's syndrome (pSS) increases the risk of…
Abstract Number: 2194 • ACR Convergence 2023
Association of Self-perceived Oral Health Status with ESSPRI Reported by Sjögren’s Syndrome Patients
Oscar E. Alvarez-González¹, Hector Guerra², Elena A. Quintana-Aguilar², Sandra P. Arroyo-Sánchez², Jesus S. Cortez-Gutierrez², Jesus Alberto Cardenas-De la Garza³, Francisco J. Torres-Quintanilla⁴, Janett Riega-Torres⁵, Cassandra Michele Skinner-Taylor⁵ and Dionicio A. Galarza-Delgado⁶, ¹Hospital Universitario "Dr. José Eleuterio González", Universidad Autónoma de Nuevo León, Monterrey, Mexico, ²Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ³Hospital Universitario "Dr. José Eleuterio González", San Nicolas, Mexico, ⁴Hospital Universitario "Dr. José Eleuterio González", UANL, Monterrey, Mexico, ⁵Hospital Universitario "Dr. José Eleuterio González", Monterrey, Mexico, ⁶Hospital Universitario UANL, Monterrey, Mexico
Background/Purpose: Salivary gland hypofunction, manifested as xerostomia in Sjögren's syndrome (SS), causes dental, language, and nutritional problems, leading to a detriment in oral health. The…
Abstract Number: 021 • 2023 Pediatric Rheumatology Symposium
Distinguishing Childhood Sjogren’s Disease in Patients Presenting with Recurrent Sialadenitis in a Multidisciplinary Clinic
Anna Holley¹ and Sara Stern², ¹University of Utah School of Medicine, Salt Lake City, UT, ²University of Utah Department of Pediatrics, Salt Lake City, UT
Background/Purpose: Sialadenitis is a common distinguishing manifestation of Childhood Sjogrens Disease (cSD). We have previously reported a surprisingly high rate of Childhood Sjogrens Disease (cSD)…
Abstract Number: 114 • 2023 Pediatric Rheumatology Symposium
Clinical Significance of SSA and SSB Antibodies in Pediatric SLE Patients: A Single Center Cohort
Yiressy Pina¹, Dawn Janysek¹, Danielle Guffey², Maria Pereira Palacios³ and Marietta De Guzman¹, ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX, ³Baylor College of Medicine, Texas Children's Hospital, Houston, TX
Background/Purpose: Anti-nuclear antibodies (ANA) are important in the diagnosis of Systemic Lupus Erythematosus (SLE). Of the disease specific ANAs, anti-dsDNA and anti- Smith antibodies carry…
Abstract Number: L13 • ACR Convergence 2022
Fetal Cardiac Targets Identify the Autoantibodies Associated with Congenital Heart Block
Stephanie Benjamin¹, Lisa Vi², Diptendu Chatterjee¹, Edgar Jaeggi¹, Marie Wahren-Herlenius³, Amelia Ruffatti⁴, Linda Hiraki⁵, Michelle Lohbihler², Lusia Sepiashvili¹, Carl Laskin⁶, Meena Fatah¹, Daniela Dominguez⁵, Lawrence Ng⁵, Anthony Gramolini², Vincent Christoffels⁷, Stephanie Protze² and Robert Hamilton⁸, ¹Hospital for Sick Children, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, ⁴Universitå di Padova, Padova, Italy, ⁵The Hospital for Sick Children, Toronto, ON, Canada, ⁶Mt. Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁷Amsterdam UMC, Amsterdam, Zuid-Holland, Netherlands, ⁸Hospital for Sick Children, Markham, ON, Canada
Background/Purpose: Autoimmune congenital heart block (CHB+) affects the fetus of mothers with anti-Ro antibodies. Anti-Ro (Ro+) antibodies (Abs) are usually present in maternal sera when…
Abstract Number: 1625 • ACR Convergence 2022
Single Cell and Spatial Transcriptomics Identifies Pathogenic Drivers of Sjogren’s Disease in Humans
Blake Warner¹, Thomas Pranzatelli², Paola Perez², Daniel Martin², Shyh-Ing Jang², Kalie Dominick², Eiko Yamada², Kevin Byrd³, Quinn Easter⁴, A. Darise Farris⁵, Christopher Lessard⁵, Amanda Oliver⁶, Raquel Bartolome-Casado⁶, Zohreh Khavandgar¹, Sarthak Gupta⁷, Sarah Teichmann⁶, Alan Baer⁸ and John Chiorini², ¹National Institutes of Health, Bethesda, MD, ²NIDCR, Bethesda, MD, ³American Dental Association, Scientific Research Institute, Gaithersburg, MD, ⁴American Dental Association, Gaithersburg, MD, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Wellcome Sanger Institute, Cambridgeshire, United Kingdom, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁸Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sjogren's Disease(SjD) is a systemic autoimmune disease characterized by exocrine dysfunction. The pathogenesis is incompletely understood, but involves gene-environment interactions leading to infiltration of…
Abstract Number: 2025 • ACR Convergence 2022
Natural History of Sjögren’s Disease from the National Institutes of Health Cohort
Brandon Law¹, Margaret Beach², Eileen Pelayo², Ilias Alevizos², Zohreh Khavandgar², Blake Warner² and Alan Baer¹, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²National Institutes of Health, Bethesda, MD
Background/Purpose: The objectives of this study were to assess the natural history of Sjögren's disease (SjD) over an interval reaching up to 32 years among…
Abstract Number: 2041 • ACR Convergence 2022
Single Cell Atlas of Minor Salivary Glands Reveals Key Differential Cellular and Functional Players in Sjögren’s and Sicca Syndrome
SABA NAYAR¹, Jason D. turner¹, Saba Asam¹, Charlotte G. Smith¹, Serena Colfrancesco², Ana Teodósio¹, Joe Flint¹, David H Gardner¹, Professor Simon Bowman³, Adam Croft¹, Andrew Filer¹, Benjamin A. Fisher¹, Christopher Buckley⁴ and Francesca Barone⁵, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Rome, Rome, Italy, ³University Hospitals Birmingham, Birmingham, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵University of Birmingham, Needham, MA
Background/Purpose: Sjögren's syndrome (SjS) shares a series of symptoms with non-SjS Sicca syndrome, a salivary gland disease characterised by glandular dysfunction and dryness. However, unlike…
Abstract Number: 1626 • ACR Convergence 2022
Unique Biological Profile of Germinal Centres Within Tertiary Lymphoid Structures in the Salivary Glands of Patients with Sjögren’s Syndrome
SABA NAYAR¹, Jason D. turner¹, Saba Asam¹, Serena Colfrancesco², Onorina Berardicurti³, Valentina Iannizzotto¹, Charlotte G Smith¹, Joe Flint¹, Ana Teodósio¹, David H Gardner¹, Professor Simon Bowman⁴, Wan-Fai Ng⁵, Adam Croft¹, Andrew Filer¹, Benjamin A. Fisher¹, Christopher Buckley⁶ and Francesca Barone⁷, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Rome, Rome, Italy, ³Rheumatology Unit, Pescara Hospital, Pescara, Italy, ⁴University Hospitals Birmingham, Birmingham, United Kingdom, ⁵Newcastle University, Newcastle, United Kingdom, ⁶University of Oxford, Oxford, United Kingdom, ⁷University of Birmingham, Needham, MA
Background/Purpose: Tertiary lymphoid structures (TLS) are accumulations of lymphoid cells that share similar cellular compartments, organization and function when compared to secondary lymphoid organs (SLOs)…
Abstract Number: 2026 • ACR Convergence 2022
Serum and Tear Autoantibodies from nor Mice as Potential Diagnostic Indicators of Local and Systemic Inflammation in Sjögren’s Syndrome
Shruti Singh Kakan¹, Yaping Ju², Maria Edman² and Sarah Hamm-Alvarez³, ¹Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California; Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, ²Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California, Los Angeles, CA, ³Department of Ophthalmology, Keck School of Medicine, Roski Eye Institute, University of Southern California; Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA
Background/Purpose: Sjögren's Syndrome (SS) is an autoimmune disease characterized by infiltration of lymphocytes into lacrimal (LG) and salivary (SG) glands and their concurrent loss of…
Abstract Number: 2042 • ACR Convergence 2022
Sjögren’s Disease and Mitochondrial Function
Biji T Kurien¹, Pharaoh Gavin², Joshua Cavett¹, Valerie Lewis³, Ambre Chambers¹, Bhaskaran Shylesh⁴, Anjum Juvaria¹, Brittany Karfonta¹, Lida Radfar¹, Astrid Rasmussen⁴, Christopher Lessard⁴, Darise Farris⁴, Kathy Sivils⁵, Kristi A Koelsch⁴, Holly Van Remmen⁴ and R. Hal Scofield¹, ¹University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²University of Washington, Seattle, WA, ³Veterans Affairs Medical Center, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Sjögren's disease (SjD) is a chronic inflammatory, autoimmune disorder with reduced lacrimal/salivary gland secretion resulting in keratoconjunctivitis sicca and xerostomia, respectively. Also, SjD patients…
Abstract Number: 1627 • ACR Convergence 2022
BAFF-var Is a New Predisposing Factor for Primary Sjögren’s Syndrome (pSS) and Impacts Disease Activity
Marie Dulin¹, Maxime Beydon², Bineta Ly³, Veronique Le Guern⁴, Raphaèle Seror⁵, Xavier Mariette⁶ and Gaetane Nocturne⁷, ¹Kremlin Bicêtre Hospital - APHP, Paris, France, ²Université Paris Cité, Paris, France, ³INSERM UMR1184, Le Kremlin Bicêtre, France, ⁴Hôpital Cochin, Paris, France, ⁵University Hospital Paris-Saclay, Le Kremlin Bicêtre, France, ⁶Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ⁷APHP, Le Kremlin Bicêtre, France
Background/Purpose: Chronic B cell activation plays a key role in pSS pathogeny. BAFF (B-cell activating factor) is largely involved in this process and positive results…
Abstract Number: 2027 • ACR Convergence 2022
Labial and Parotid Salivary Gland Histopathology in Primary Sjögren’s Syndrome
Uzma Nakshbandi¹, Martha S. van Ginkel¹, Silvia Liefers², Hendrika Bootsma², Fred Spijkervet², Arjan Vissink¹, Bert van der Vegt¹ and Frans Kroese², ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: Salivary gland involvement is a hallmark of disease in primary Sjögren's syndrome (pSS). This is reflected by the prominent role of a positive biopsy…
Abstract Number: 2043 • ACR Convergence 2022
What Does Isolated Anti-Ro52 Antibody Positivity Mean in Sjögren’s Syndrome?
Eléonore Bettacchioli¹, Alain Saraux², Alice Tison³, Divi CORNEC⁴, Maryvonne Dueymes¹, Marta Alarcon-Riquelme⁵ and Valerie Devauchelle⁶, ¹Immunology and Immunotherapy Laboratory, CHRU Brest, Brest, France, ²CHU Brest, Brest, France, ³Rheumatology Department, CHRU Brest, Brest, France, ⁴CHRU Brest, Brest, France, ⁵Center for Genomics and Oncological Research (GENYO), Granada, Spain, ⁶Université de Bretagne Occidentale, Brest, France
Background/Purpose: Primary Sjögren's syndrome (pSS) is a systemic autoimmune disease characterized by a triad of dryness, pain and fatigue in affected patients. Its diagnosis is…
Abstract Number: 0013 • ACR Convergence 2022
Binding of CXCL13 with Heparan Sulfate of Syndecan-1 Plays an Important Role in Pathogenesis of Sjögren’s Syndrome
Eon Jeong Nam¹, Na Ri Kim¹ and Gun Woo Kim², ¹Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea, ²Daegu Fatima Hospital, Daegu, Republic of Korea
Background/Purpose: Sjögren's syndrome (SS) is a chronic autoimmune disorder with lymphocytic infiltration in exocrine and non-exocrine epithelia, in which epithelial cells play a critical role…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.